Scarica l'app Stockscreener
26.22
2.49%
-0.67
Dopo l'orario di chiusura:
26.20
-0.02
-0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$26.89
Aprire:
$26.55
Volume 24 ore:
5.61M
Relative Volume:
0.56
Capitalizzazione di mercato:
$10.20B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-3.0034
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-1.76%
1M Prestazione:
-15.34%
6M Prestazione:
-26.20%
1 anno Prestazione:
-69.74%
Intervallo 1D:
$26.01
$26.60
Intervallo di 1 settimana:
$26.01
$28.59
Portata 52W:
$23.15
$86.80
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
26.22 | 10.93B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Feds Lose Bid To Seal In Vax Patent Case Against Moderna - Law360
Moderna (NASDAQ:MRNA) Stock Price Up 6.6%Here's What Happened - MarketBeat
Judge Rejects Army Redactions in Moderna Covid-Shot Patent Case - Bloomberg Law News
At Moderna, harnessing our differences is the key to solving problems - The Globe and Mail
28,886 Shares in Moderna, Inc. $MRNA Acquired by Freestone Capital Holdings LLC - MarketBeat
Neuberger Berman Group LLC Increases Stock Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Sees Unusually Large Options Volume (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. $MRNA Shares Acquired by Invesco Ltd. - MarketBeat
Pediatrics group defies CDC and recommends COVID shots for kids - Seeking Alpha
National Pension Service Cuts Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates - Corpus Christi Caller-Times
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline - MSN
Moderna Fails To Block UPC Claims Against Subsidiaries - Law360
Biopharma layoffs rise as drugmakers tighten belts and reorganize - Pharma Voice
mRNA Technology Market Is Booming So Rapidly | Pfizer, Moderna, BioNTech - openPR.com
Charles Schwab Investment Management Inc. Raises Stake in Moderna, Inc. $MRNA - MarketBeat
Blair William & Co. IL Trims Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Who Owns Moderna? Biggest Shareholders and Recent Insider Trades - TIKR.com
Coronavirus Update: Moderna Shows 100% Efficacy In Teens - insights.citeline.com
If You're in Your 30s, Consider Buying These 2 Healthcare Stocks - AOL.com
If You're in Your 30s, Consider Buying These 2 Healthcare Stocks - The Motley Fool
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot - MSN
Stock Analysis | Moderna OutlookWeak Technicals and Mixed Market Signals - AInvest
Moderna Inc Expands Beyond Respiratory Vaccines – Is Diversification the Key to Long-Term Success? - Smartkarma
Moderna to lay off 10% of staff this year - MSN
Moderna Inc's GF Score Indicates Potential Underperformance - AInvest
Deutsche Bank AG Decreases Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Stock Surges 4.98% as Trading Volume Jumps 70% to 402nd Market Activity Rank - AInvest
A US FDA Move to Revoke Pfizer’s Pediatric COVID-19 Vaccine EUA Could Raise Supply Questions - insights.citeline.com
Moderna to Cut 10% of Staff to Offset Slowing Covid Business - MSN
Short bets on S&P 500 Healthcare sector ease in July; Moderna remains most heavily shorted stock - Seeking Alpha
Moderna layoffs: U.S. Pharma giant announces massive job cuts, to have less than 5,000 employees, MRNA stocks sink - MSN
Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Vanguard Group Inc. Buys 72,763 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
ASR Vermogensbeheer N.V. Invests $614,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna’s SWOT analysis: mRNA pioneer faces pivotal year for stock By Investing.com - Investing.com Australia
Moderna’s SWOT analysis: mRNA pioneer faces pivotal year for stock - Investing.com
Rate Cut Rationale and Healthcare Gains: Evaluating the Surge in Biogen, Moderna, and Align Tech - AInvest
Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know - TradingView
Moderna Stock Jumps as NIH Chief Tempers Administration’s Attack on mRNA - Barron's
Notable Stocks Rise on August 13th: Paramount, Coinbase, Warner Bros., AMD, and Moderna Lead the Way. - AInvest
Is Moderna Stock A Sell After Cutting Its Sales Outlook — Again? - Investor's Business Daily
Multi Factor Analysis Ranks Moderna Inc. as Strong BuyShare Buyback & Free Safe Entry Trade Signal Reports - 선데이타임즈
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech - Democrat and Chronicle
3 Reasons to Avoid MRNA and 1 Stock to Buy Instead - Yahoo Finance
The 5 Most Interesting Analyst Questions From Moderna’s Q2 Earnings Call - Yahoo Finance
Other Nations Move Toward Making Their Own Vaccines as US Cuts Funding - Bloomberg.com
Moderna's COVID-19 Vaccine Faces Regulatory Threats, RSV Vaccine Sales Uncertain, and Clinical Programs in Development - AInvest
Moderna, Teleflex, Envista, Enovis, and UnitedHealth Shares Are Soaring, What You Need To Know - Yahoo Finance
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency - Benzinga
KDCA readies mRNA vaccines, tech for COVID-19, future outbreaks - BioWorld MedTech
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.55%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):